Close

move up move left move right move bottom

More than 26 million people worldwide have been prescribed XARELTO®1

DVT Prophylaxis After Knee or Hip Replacement Surgery

Proven efficacy and safety profile versus enoxaparin

DVT = deep vein thrombosis.

 

Indications

 

IMPORTANT SAFETY INFORMATION

 

Indication and Important saftey Information

 

  • Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® (rivaroxaban) and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
  • Treatment of deep vein thrombosis (DVT).
  • Treatment of pulmonary embolism (PE).
  • Reduction in the risk of recurrence of DVT and of PE following initial 6 months treatment for DVT and/or PE.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery.

Reference:

  1. Data on file. Based on Bayer Healthcare AG utilizing IMS MIDAS Database: Monthly Sales through Oct 2016.